... Reuters reported the company as saying. Samsung Biologics added that the change to fair value and the ensuing net profit was approved by KPMG Korea, Deloitte Korea and PricewaterhouseCoopers Korea, and the issue wasn't raised by the FSS when the company released the 2015 books in 2016.
Delivered by KPMG Today (@KPMG_TO)
Article continues here
Follow @KPMG_TO on Twitter to get latest updates
